temozolomide + trastuzumab emtansine

This is a combination therapy consisting of two agents: temozolomide, an oral alkylating agent, and trastuzumab emtansine (T-DM1), an antibody-drug conjugate. Temozolomide acts as a DNA-methylating agent that induces cytotoxicity in dividing tumor cells. Trastuzumab emtansine combines the HER2-targeting monoclonal antibody trastuzumab with the microtubule inhibitor DM1 via a stable linker, enabling targeted delivery of cytotoxic payload to HER2-overexpressing cancer cells. The combination has been investigated primarily for the prevention of additional brain metastases in patients with HER2-positive breast cancer who have already developed brain metastases and received local treatment. Phase 1 studies indicate this regimen is safe and well tolerated, with main toxicities being mild laboratory abnormalities such as thrombocytopenia and leukopenia[1][4][2].

Brand names

Kadcyla (for trastuzumab emtansine)

Other names

ado-trastuzumab emtansine + temozolomideT-DM1 + temozolomide